SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Miami Beach, Florida and currently employs 63 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Follow-Up Questions
Who is the CEO of SAB Biotherapeutics Inc?
Mr. Samuel Reich is the Executive Chairman of the Board of SAB Biotherapeutics Inc, joining the firm since 2021.
What is the price performance of SABS stock?
The current price of SABS is $2.45, it has decreased 0.76% in the last trading day.
What are the primary business themes or industries for SAB Biotherapeutics Inc?
SAB Biotherapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is SAB Biotherapeutics Inc market cap?
SAB Biotherapeutics Inc's current market cap is $25.5M
Is SAB Biotherapeutics Inc a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for SAB Biotherapeutics Inc, including 3 strong buy, 7 buy, 1 hold, 0 sell, and 3 strong sell
